PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22608542-12 2013 The use of high-dose vandetanib alone may warrant further investigation in patients with docetaxel-resistant AIPC overexpressing VEGFR/EGFR pathways. vandetanib 21-31 epidermal growth factor receptor Homo sapiens 130-134 34551970-3 2022 Vandetanib, an inhibitor of VEGFR/RET/EGFR, was found to target ACVR1 (Kd=150nM) and reduce DIPG cell viability in vitro, but has limited ability to cross the blood-brain-barrier. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 38-42 34981062-3 2021 Vandetanib, which targets the vascular endothelial growth factor receptor (VEGFR), the epidermal growth factor receptor (EGFR), and the RET-tyrosine kinase showed the most promising results on inhibition versus toxic effect on SARS-CoV-2-infected Caco-2 and A549-hACE2 cells (IC 50 0.79 muM) while also showing a reduction of > 3 log TCID 50 /mL for HCoV-229E. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 87-119 34981062-3 2021 Vandetanib, which targets the vascular endothelial growth factor receptor (VEGFR), the epidermal growth factor receptor (EGFR), and the RET-tyrosine kinase showed the most promising results on inhibition versus toxic effect on SARS-CoV-2-infected Caco-2 and A549-hACE2 cells (IC 50 0.79 muM) while also showing a reduction of > 3 log TCID 50 /mL for HCoV-229E. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 121-125 35331723-2 2022 Vandetanib, a dual tyrosine kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, was broadly effective in treating a variety of human solid tumors. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 48-80 33923880-1 2021 A tyrosine kinase inhibitor, vandetanib (Van), is an anticancer drug affecting the signaling of VEGFR, EGFR and RET protooncogenes. vandetanib 29-39 epidermal growth factor receptor Homo sapiens 97-101 35330879-13 2022 DrugBank database search identified several FDA approved drug targets including anti-EGFR Vandetanib used to treat thyroid cancer in addition to others that may prove useful in treating PTC. vandetanib 90-100 epidermal growth factor receptor Homo sapiens 85-89 33929994-2 2021 The objective of this study was to investigate how embolization-induced hypoxia may affect antitumoural activity of vandetanib, an inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR), in the context of hepatocellular carcinoma (HCC) treatment. vandetanib 116-126 epidermal growth factor receptor Homo sapiens 200-232 33929994-2 2021 The objective of this study was to investigate how embolization-induced hypoxia may affect antitumoural activity of vandetanib, an inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR), in the context of hepatocellular carcinoma (HCC) treatment. vandetanib 116-126 epidermal growth factor receptor Homo sapiens 190-194 33923880-1 2021 A tyrosine kinase inhibitor, vandetanib (Van), is an anticancer drug affecting the signaling of VEGFR, EGFR and RET protooncogenes. vandetanib 41-44 epidermal growth factor receptor Homo sapiens 97-101 33721621-1 2021 BACKGROUND: Preclinical studies suggest that combining vandetanib (VAN), a multi-tyrosine kinase inhibitor of rearranged during transfection (RET) proto-oncogene, vascular endothelial growth factor receptor (VEGFR), and epidermal growth factor receptor (EGFR), with everolimus (EV), a mammalian target of rapamycin (mTOR) inhibitor, may improve antitumor activity. vandetanib 55-65 epidermal growth factor receptor Homo sapiens 220-252 33721621-1 2021 BACKGROUND: Preclinical studies suggest that combining vandetanib (VAN), a multi-tyrosine kinase inhibitor of rearranged during transfection (RET) proto-oncogene, vascular endothelial growth factor receptor (VEGFR), and epidermal growth factor receptor (EGFR), with everolimus (EV), a mammalian target of rapamycin (mTOR) inhibitor, may improve antitumor activity. vandetanib 55-65 epidermal growth factor receptor Homo sapiens 209-213 33721621-1 2021 BACKGROUND: Preclinical studies suggest that combining vandetanib (VAN), a multi-tyrosine kinase inhibitor of rearranged during transfection (RET) proto-oncogene, vascular endothelial growth factor receptor (VEGFR), and epidermal growth factor receptor (EGFR), with everolimus (EV), a mammalian target of rapamycin (mTOR) inhibitor, may improve antitumor activity. vandetanib 67-70 epidermal growth factor receptor Homo sapiens 220-252 33721621-1 2021 BACKGROUND: Preclinical studies suggest that combining vandetanib (VAN), a multi-tyrosine kinase inhibitor of rearranged during transfection (RET) proto-oncogene, vascular endothelial growth factor receptor (VEGFR), and epidermal growth factor receptor (EGFR), with everolimus (EV), a mammalian target of rapamycin (mTOR) inhibitor, may improve antitumor activity. vandetanib 67-70 epidermal growth factor receptor Homo sapiens 209-213 31233590-1 2019 Vandetanib is a once-daily oral multikinase inhibitor that targets the rearranged during transfection (RET) tyrosine kinase, vascular endothelial growth factor receptor, and epidermal growth factor receptor. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 174-206 32800552-0 2020 Vandetanib inhibits cell growth in EGFR-expressing cutaneous squamous cell carcinoma. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 35-39 32800552-3 2020 Vandetanib is a multiple tyrosine kinase targeting vascular endothelial growth factor receptor-2 (VEGFR2), EGFR, and the rearranged during transfection (RET) proto-oncogene. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 99-103 32800552-10 2020 Mechanistically, vandetanib suppresses the phosphorylation of EGFR in SCC cells. vandetanib 17-27 epidermal growth factor receptor Homo sapiens 62-66 32800552-12 2020 In conclusion, we identified vandetanib as a novel therapeutic option for cutaneous SCC, especially in tumors with high EGFR expression. vandetanib 29-39 epidermal growth factor receptor Homo sapiens 120-124 31299389-0 2019 Vandetanib sensitizes head and neck squamous cell carcinoma to photodynamic therapy through modulation of EGFR-dependent DNA repair and the tumour microenvironment. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 106-110 31299389-2 2019 PURPOSE: We investigated vandetanib, which selectively blocks EGFR and vascular endothelial growth factor receptor-2 (VEGFR-2), to enhance the efficacy of PDT. vandetanib 25-35 epidermal growth factor receptor Homo sapiens 62-66 31299389-7 2019 Next, combined vandetanib and PDT resulted in significant tumour growth delay in vivo that is linked to reduction of PDT-induced EGFR phosphorylation and cellular proliferation, along with loss of tumour vasculature. vandetanib 15-25 epidermal growth factor receptor Homo sapiens 129-133 33296710-1 2021 Vandetanib (ZD6474, Zactima , Caprelsa ) is a newly developed dual tyrosine kinase inhibitor of vascular endothelial growth factor and epidermal growth factor receptor. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 135-167 33296710-1 2021 Vandetanib (ZD6474, Zactima , Caprelsa ) is a newly developed dual tyrosine kinase inhibitor of vascular endothelial growth factor and epidermal growth factor receptor. vandetanib 12-18 epidermal growth factor receptor Homo sapiens 135-167 32336008-1 2020 OBJECTIVES: To assess the efficacy and tolerability of the dual EGFR/VEGFR inhibitor, vandetanib, in combination with carboplatin and gemcitabine in the first line treatment of patients with advanced urolthelial cancer (UC) who were unsuitable for cisplatin. vandetanib 86-96 epidermal growth factor receptor Homo sapiens 64-68 30860683-1 2019 OBJECTIVES: Vandetanib lenvatinib, and cabozantinib are tyrosine kinase inhibitors (TKIs) targeting VEGFR subtypes 1 and 2, EGFR and the RET-tyrosine kinase, thus considered as multiple TKIs. vandetanib 12-22 epidermal growth factor receptor Homo sapiens 102-106 29363191-2 2018 In this study, we developed a high epidermal growth factor receptor (EGFR)-expression cell membrane chromatography (CMC) method to investigate the binding characteristics between EGFR and the ligands gefitinib, erlotinib, canertinib, afatinib, and vandetanib. vandetanib 248-258 epidermal growth factor receptor Homo sapiens 69-73 30555244-1 2018 Objective: Vandetanib, also known as ZD6474, has recently been proved to be a clinical drug for cancer by targeting vascular endothelial growth factor receptor 2 (VEGFR2), EGFR, and RET tyrosine kinases. vandetanib 11-21 epidermal growth factor receptor Homo sapiens 164-168 30555244-1 2018 Objective: Vandetanib, also known as ZD6474, has recently been proved to be a clinical drug for cancer by targeting vascular endothelial growth factor receptor 2 (VEGFR2), EGFR, and RET tyrosine kinases. vandetanib 37-43 epidermal growth factor receptor Homo sapiens 164-168 30321910-15 2018 The certainty of evidence is very low, but treatment may reduce quality of life compared to observation.Treatment with an EGFR TKI (vandetanib) for women with relapsed EOC may make little or no difference in overall survival (HR 1.25, 95% CI 0.80 to 1.95; one study; 129 participants; low-certainty evidence) and may make little or no difference in progression-free survival (HR 0.99, 95% CI 0.69 to 1.42; one study; 129 participants; very low-certainty evidence). vandetanib 132-142 epidermal growth factor receptor Homo sapiens 122-126 29363191-2 2018 In this study, we developed a high epidermal growth factor receptor (EGFR)-expression cell membrane chromatography (CMC) method to investigate the binding characteristics between EGFR and the ligands gefitinib, erlotinib, canertinib, afatinib, and vandetanib. vandetanib 248-258 epidermal growth factor receptor Homo sapiens 179-183 29517106-4 2018 Furthermore, vandetanib inhibited EGFR, AKT and ERK1/2 phosphorylation and downregulated cyclin D1 in ATC cells. vandetanib 13-23 epidermal growth factor receptor Homo sapiens 34-38 28132823-4 2017 Vandetanib is an MTKi which acts against such targets as vascular endothelial growth factor receptor (VEGFR) and epithelial growth factor receptor (EGFR) and has demonstrated modest activity against hepatocellular carcinoma (HCC), albeit with some dose-limiting cardiac toxicity. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 113-146 26986978-2 2017 Vandetanib, a small molecule receptor tyrosine kinase inhibitor of VEGFR-2, VEGFR-3, RET, and EGFR, demonstrated synergy with radiation and chemotherapy in preclinical models. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 68-72 28132823-4 2017 Vandetanib is an MTKi which acts against such targets as vascular endothelial growth factor receptor (VEGFR) and epithelial growth factor receptor (EGFR) and has demonstrated modest activity against hepatocellular carcinoma (HCC), albeit with some dose-limiting cardiac toxicity. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 103-107 28259610-2 2017 Vandetanib is a novel tyrosine kinase inhibitor of VEGFR2, RET, and EGFR, all of which are in involved in the pathogenesis of pancreatic cancer. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 52-56 27983649-1 2016 Sixteen novel epidermal growth factor receptor (EGFR)/vascular endothelial growth factor (VEGF)-2 inhibitors (nitroimidazole-substituted 4-anilinoquinazoline derivatives (16a-p)) were designed and prepared via the introduction of a nitroimidazole group in the piperidine side chain and modification on the aniline moiety of vandetanib. vandetanib 324-334 epidermal growth factor receptor Homo sapiens 14-46 27983649-2 2016 Preliminary biological tests showed that comparing with vandetanib, some target compounds exhibited excellent EGFR inhibitory activities and anti-proliferative over A549/H446 cells in hypoxia. vandetanib 56-66 epidermal growth factor receptor Homo sapiens 110-114 27798882-2 2016 Vandetanib is a tyrosine kinase inhibitor with inhibitory activity against vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR). vandetanib 0-10 epidermal growth factor receptor Homo sapiens 123-155 27711083-3 2016 Vandetanib, an inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor and rearranged during transfection tyrosine kinases, is a potent radiosensitiser in xenograft models. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 73-105 27798882-2 2016 Vandetanib is a tyrosine kinase inhibitor with inhibitory activity against vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR). vandetanib 0-10 epidermal growth factor receptor Homo sapiens 157-161 27250896-5 2016 This article will provide an update on different treatment options available for patients with EGFR wild-type advanced NSCLC who relapse after first-line therapy, which includes essentially ramucirumab, vandetanib, nivolumab, and pembrolizumab and considerations that may allow clinicians to a better choice of agent for second-line therapy. vandetanib 203-213 epidermal growth factor receptor Homo sapiens 95-99 26050198-1 2015 ZD6474, a small molecule VEGFR and EGFR tyrosine kinase inhibitor, has been considered as a promising tumor-targeted drug in various malignancies. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 26-30 25352401-1 2016 BACKGROUND: Vandetanib, added to cisplatin and radiation therapy (RT) overcomes chemoradiation therapy (CRT) and epidermal growth factor receptor (EGFR) inhibitor resistance in head and neck squamous cell carcinoma (HNSCC) lines and models. vandetanib 12-22 epidermal growth factor receptor Homo sapiens 113-145 25352401-1 2016 BACKGROUND: Vandetanib, added to cisplatin and radiation therapy (RT) overcomes chemoradiation therapy (CRT) and epidermal growth factor receptor (EGFR) inhibitor resistance in head and neck squamous cell carcinoma (HNSCC) lines and models. vandetanib 12-22 epidermal growth factor receptor Homo sapiens 147-151 26832794-0 2016 EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib. vandetanib 73-83 epidermal growth factor receptor Homo sapiens 0-4 26832794-8 2016 The effect of the TKI vandetanib on proliferation and tumor growth response of MCF-7 cells was dependent upon expression of TFAP2C, and dual KD of RET and EGFR eliminated the effects of vandetanib. vandetanib 186-196 epidermal growth factor receptor Homo sapiens 155-159 26832794-11 2016 Response to vandetanib was mediated through the TFAP2C target genes EGFR and RET. vandetanib 12-22 epidermal growth factor receptor Homo sapiens 68-72 26050198-2 2015 EGFR and cyclooxygenase-2 (COX-2) were found overexpressed in osteosarcoma in previous reports, so here we tried to explore the anti-osteosarcoma effect of ZD6474 alone or combination with celecoxib, a COX-2 inhibitor. vandetanib 156-162 epidermal growth factor receptor Homo sapiens 0-4 26050198-3 2015 The data demonstrated that ZD6474 inhibited the growth of osteosarcoma cells, and promoted G1-phase cell cycle arrest and apoptosis by inhibiting the activity of EGFR tyrosine kinase, and consequently suppressing its downstream PI3k/Akt and MAPK/ERK pathway. vandetanib 27-33 epidermal growth factor receptor Homo sapiens 162-166 24924416-3 2014 We assessed whether vandetanib, an inhibitor of VEGF, epidermal growth factor receptor and RET signalling, improved uNTx response when added to fulvestrant (F) in breast cancer patients with bone metastases. vandetanib 20-30 epidermal growth factor receptor Homo sapiens 54-86 25503302-2 2015 Vandetanib inhibits epidermal growth factor receptor and vascular endothelial growth factor receptor 2. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 20-52 24412287-6 2014 Clinical trials with EGFR targeted agents, including cetuximab, erlotinib, and vandetanib, are currently under way, some with promising preliminary results. vandetanib 79-89 epidermal growth factor receptor Homo sapiens 21-25 25089348-2 2014 Vandetanib is a multitargeted tyrosine kinase inhibitor that selectively blocks VEGFR-2, the EGFR and RET tyrosine kinases. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 81-85 25910950-1 2015 PURPOSE: Vandetanib, a tyrosine kinase inhibitor of KDR (VEGFR2), EGFR, and RET, may enhance sensitivity to chemotherapy and radiation. vandetanib 9-19 epidermal growth factor receptor Homo sapiens 58-62 26170630-1 2015 Vandetanib is a once-daily orally available tyrosine kinase inhibitor that works by blocking RET (REarranged during Transfection), vascular endothelial growth factor receptor (VEGFR-2, VEGFR-3), and epidermal growth factor receptor and to a lesser extent VEGFR-1, which are important targets in thyroid cancer (TC). vandetanib 0-10 epidermal growth factor receptor Homo sapiens 199-231 25887790-6 2015 Analyses of individual cells treated with the multi-tyrosine kinase inhibitor vandetanib reveal that, while the ribosomal genes and many other so-called house-keeping genes reduce their relative expression diversity during the drug treatment, the genes that are directly targeted by vandetanib, the EGFR and RET genes, remain constant. vandetanib 78-88 epidermal growth factor receptor Homo sapiens 299-303 25887790-6 2015 Analyses of individual cells treated with the multi-tyrosine kinase inhibitor vandetanib reveal that, while the ribosomal genes and many other so-called house-keeping genes reduce their relative expression diversity during the drug treatment, the genes that are directly targeted by vandetanib, the EGFR and RET genes, remain constant. vandetanib 283-293 epidermal growth factor receptor Homo sapiens 299-303 25057173-0 2014 EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer. vandetanib 37-47 epidermal growth factor receptor Homo sapiens 0-4 25057173-3 2014 This study evaluated epidermal growth factor receptor (EGFR) gene mutation, copy number gain, and protein expression, and KRAS gene mutation, in pretreatment tumor samples as potential biomarkers predicting benefit from vandetanib as second-line treatment of NSCLC. vandetanib 220-230 epidermal growth factor receptor Homo sapiens 21-53 25057173-8 2014 Similarly, patients with EGFR mutation or FISH-positive tumor samples who received vandetanib had an increased chance of objective tumor response (odds ratios 3.34, CI 0.8-13.89, and 3.90, CI 1.02-14.82, respectively). vandetanib 83-93 epidermal growth factor receptor Homo sapiens 25-29 25057173-10 2014 CONCLUSIONS: High EGFR gene copy number or activating EGFR mutations may identify patient subgroups who receive increased clinical benefit from vandetanib in combination with docetaxel in second-line NSCLC. vandetanib 144-154 epidermal growth factor receptor Homo sapiens 18-22 25057173-10 2014 CONCLUSIONS: High EGFR gene copy number or activating EGFR mutations may identify patient subgroups who receive increased clinical benefit from vandetanib in combination with docetaxel in second-line NSCLC. vandetanib 144-154 epidermal growth factor receptor Homo sapiens 54-58 25117183-1 2014 BACKGROUND AND OBJECTIVE: Vandetanib is a selective inhibitor of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR) and rearranged during transfection (RET) signalling, indicated for the treatment of medullary thyroid cancer. vandetanib 26-36 epidermal growth factor receptor Homo sapiens 118-150 25117183-1 2014 BACKGROUND AND OBJECTIVE: Vandetanib is a selective inhibitor of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR) and rearranged during transfection (RET) signalling, indicated for the treatment of medullary thyroid cancer. vandetanib 26-36 epidermal growth factor receptor Homo sapiens 111-115 24671507-1 2014 PURPOSE: To investigate the efficacy and safety of combining vandetanib, an orally available multi-targeted tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR), with bicalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). vandetanib 61-71 epidermal growth factor receptor Homo sapiens 185-189 24502390-6 2014 EXPERT OPINION: Vandetanib targets multiple cell-signaling pathways involved in the molecular pathogenesis of thyroid cancer, namely vascular endothelial growth factor receptor-2, epidermal growth factor receptor and rearranged during transfection receptor. vandetanib 16-26 epidermal growth factor receptor Homo sapiens 180-212 24709487-1 2014 BACKGROUND: Vandetanib is an oral tyrosine kinase inhibitor of VEGFR-2/3, EGFR and RET, which has demonstrated clinical activity as a single agent and in combination with taxanes. vandetanib 12-22 epidermal growth factor receptor Homo sapiens 64-68 23487538-2 2013 Vandetanib, a tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor 2, epidermal growth factor receptor, and RET, has been approved by the FDA for the treatment of locally advanced or metastatic MTC. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 103-135 23799852-2 2013 We investigated the autophagy-inducing effects of ZD6474, a small-molecule inhibitor that blocks activities of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and RET tyrosine kinases. vandetanib 50-56 epidermal growth factor receptor Homo sapiens 164-196 23799852-2 2013 We investigated the autophagy-inducing effects of ZD6474, a small-molecule inhibitor that blocks activities of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and RET tyrosine kinases. vandetanib 50-56 epidermal growth factor receptor Homo sapiens 157-161 24005613-3 2013 Vandetanib is an oral once daily administered inhibitor of VEGFR-, EGFR- and RET-signaling with activity in combination with chemotherapy in some solid tumours. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 60-64 23640345-2 2013 SUMMARY: Vandetanib is a small-molecule inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor, and receptor tyrosine kinase signaling pathways, which are involved in the pathogenesis of medullary thyroid cancer (MTC). vandetanib 9-19 epidermal growth factor receptor Homo sapiens 98-130 23584298-12 2013 Although vandetanib improved median PFS in EGFR mutation patients with epidermal growth factor receptor tyrosine kinase inhibitor-resistance compared with EGFR wild-type, there was no OS advantage. vandetanib 9-19 epidermal growth factor receptor Homo sapiens 43-47 23584298-12 2013 Although vandetanib improved median PFS in EGFR mutation patients with epidermal growth factor receptor tyrosine kinase inhibitor-resistance compared with EGFR wild-type, there was no OS advantage. vandetanib 9-19 epidermal growth factor receptor Homo sapiens 71-103 23274758-0 2013 Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 27-31 23274758-6 2013 Both gefitinib and vandetanib suppressed the activation of EGFR and MAPK in H1650 cells, although phosphorylated AKT levels were not affected. vandetanib 19-29 epidermal growth factor receptor Homo sapiens 59-63 23274758-10 2013 In conclusion, vandetanib might be effective in NSCLC with EGFR mutations that lack PTEN expression. vandetanib 15-25 epidermal growth factor receptor Homo sapiens 59-63 23274758-11 2013 The contribution of PTEN absence to vandetanib activity in NSCLC cells harboring EGFR mutations should be further examined. vandetanib 36-46 epidermal growth factor receptor Homo sapiens 81-85 23584298-13 2013 Although vandetanib is no longer in development in NSCLC, identification of a molecular phenotype that responds to dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition would contribute to the field. vandetanib 9-19 epidermal growth factor receptor Homo sapiens 120-152 23231950-1 2013 Vandetanib (ZD6474, Caprelsa, AstraZeneca), an oral small-molecule tyrosine kinase inhibitor (TKI) that targets the rearranged during transfection receptor (RET), VEGF receptor (VEGFR2-3), and EGF receptor (EGFR), is the first systemic therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of symptomatic or progressive advanced medullary thyroid cancer (MTC). vandetanib 0-10 epidermal growth factor receptor Homo sapiens 164-176 23231950-1 2013 Vandetanib (ZD6474, Caprelsa, AstraZeneca), an oral small-molecule tyrosine kinase inhibitor (TKI) that targets the rearranged during transfection receptor (RET), VEGF receptor (VEGFR2-3), and EGF receptor (EGFR), is the first systemic therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of symptomatic or progressive advanced medullary thyroid cancer (MTC). vandetanib 0-10 epidermal growth factor receptor Homo sapiens 179-183 23231950-1 2013 Vandetanib (ZD6474, Caprelsa, AstraZeneca), an oral small-molecule tyrosine kinase inhibitor (TKI) that targets the rearranged during transfection receptor (RET), VEGF receptor (VEGFR2-3), and EGF receptor (EGFR), is the first systemic therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of symptomatic or progressive advanced medullary thyroid cancer (MTC). vandetanib 12-18 epidermal growth factor receptor Homo sapiens 164-176 23177099-2 2013 Vandetanib, targeting epidermal growth factor receptor and vascular endothelial growth factor receptor signalling in NSCLC, has recently been evaluated in combination chemotherapy in advanced NSCLC. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 22-54 23202050-3 2013 Vandetanib selectively targets RET, vascular endothelial growth factor receptor-2, and epidermal growth factor receptor dependent signaling. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 87-119 22307735-0 2012 Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma. vandetanib 20-30 epidermal growth factor receptor Homo sapiens 39-43 23099652-1 2012 Vandetanib is a once-daily multitargeted tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and the rearranged-during-transfection oncogene. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 117-149 22307735-2 2012 Vandetanib is a small-molecule tyrosine kinase inhibitor (TKI) with dual specificity for EGFR and VEGFR. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 89-93 22307735-9 2012 The antitumor effects of vandetanib appear to be exerted via the EGFR inhibitory effect of the compound. vandetanib 25-35 epidermal growth factor receptor Homo sapiens 65-69 22898678-2 2012 We aimed to assess efficacy and safety of vandetanib, a tyrosine kinase inhibitor of RET, VEGFR and EGFR signalling, in this setting. vandetanib 42-52 epidermal growth factor receptor Homo sapiens 91-95 22715896-1 2012 Vandetanib, an orally active, small-molecule, multitargeted tyrosine kinase inhibitor, demonstrates potent inhibitory activity against vascular endothelial growth factor receptor (VEGFR)-2 and -3, epidermal growth factor receptor (EGFR) and the rearranged during transfection (RET) tyrosine kinase receptor. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 197-229 22484209-3 2012 The aim of this study was to investigate the effect of vandetanib, an oral tyrosine kinase inhibitor of EGFR, VEGFR 2 and RET kinases, on the functionality of P-gp after a 24h-treatment at therapeutic concentration (2muM), and its ability to increase the cytotoxicity of chemotherapeutic agents in multidrug resistance cancer cells. vandetanib 55-65 epidermal growth factor receptor Homo sapiens 104-108 22548830-0 2012 Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance. vandetanib 46-56 epidermal growth factor receptor Homo sapiens 19-23 22667325-3 2012 Molecules such as vandetanib that inhibit VEGFR and EGFR have also been reported to inhibit other receptors, including RET and additional kinases, and may be beneficial in treating patients with solid tumors. vandetanib 18-28 epidermal growth factor receptor Homo sapiens 43-47 22715896-1 2012 Vandetanib, an orally active, small-molecule, multitargeted tyrosine kinase inhibitor, demonstrates potent inhibitory activity against vascular endothelial growth factor receptor (VEGFR)-2 and -3, epidermal growth factor receptor (EGFR) and the rearranged during transfection (RET) tyrosine kinase receptor. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 181-185 22505191-2 2012 Here, we present a combination treatment of temozolomide (TMZ), a blood-brain barrier penetrating DNA alkylating agent, and ZD6474 (vandetanib), a VEGFR2 and EGFR dual-targeting anti-angiogenic agent, as a novel treatment strategy for GBM. vandetanib 124-130 epidermal growth factor receptor Homo sapiens 148-152 22505191-2 2012 Here, we present a combination treatment of temozolomide (TMZ), a blood-brain barrier penetrating DNA alkylating agent, and ZD6474 (vandetanib), a VEGFR2 and EGFR dual-targeting anti-angiogenic agent, as a novel treatment strategy for GBM. vandetanib 132-142 epidermal growth factor receptor Homo sapiens 148-152 21046425-1 2012 Vandetanib is an orally active small molecule tyrosine kinase inhibitor (TKI) with activity against several pathways implicated in malignancy including the vascular endothelial growth factor receptor pathway, the epidermal growth factor receptor pathway, the platelet derived growth factor receptor beta pathway, and REarranged during Transfection pathway. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 213-245 22343387-5 2012 SUMMARY: Recently, vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor (VEGFR) 2 and VEGFR 3, RET, and epidermal growth factor receptor (EGFR), was approved for the treatment of adults with symptomatic or progressive MTC. vandetanib 19-29 epidermal growth factor receptor Homo sapiens 102-106 22343387-5 2012 SUMMARY: Recently, vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor (VEGFR) 2 and VEGFR 3, RET, and epidermal growth factor receptor (EGFR), was approved for the treatment of adults with symptomatic or progressive MTC. vandetanib 31-37 epidermal growth factor receptor Homo sapiens 102-106 22646768-4 2012 This study demonstrated that treatment of NSCLC cells with vandetanib, a TKI of EGFR and VEGF receptor, and fulvestrant showed greater efficacy for inhibition of cell proliferation in vitro or xenograft tumor growth in vivo than either drug alone. vandetanib 59-69 epidermal growth factor receptor Homo sapiens 80-84 22245891-2 2012 The present study evaluated the efficacy and safety of vandetanib, an oral inhibitor of both VEGFR and EGFR, in patients with unresectable advanced HCC. vandetanib 55-65 epidermal growth factor receptor Homo sapiens 94-98 22370318-0 2012 Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). vandetanib 0-10 epidermal growth factor receptor Homo sapiens 107-139 22370318-1 2012 PURPOSE: Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor (EGFR), and RET signaling. vandetanib 9-19 epidermal growth factor receptor Homo sapiens 99-131 22370318-1 2012 PURPOSE: Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor (EGFR), and RET signaling. vandetanib 9-19 epidermal growth factor receptor Homo sapiens 133-137 22370318-2 2012 This placebo-controlled trial assessed whether vandetanib conferred an overall survival benefit in patients with advanced non-small-cell lung cancer (NSCLC) after prior treatment with an EGFR tyrosine kinase inhibitor and one or two chemotherapy regimens. vandetanib 47-57 epidermal growth factor receptor Homo sapiens 187-191 22378813-1 2012 BACKGROUND: Vandetanib is an oral inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor, and rearranged during transfection tyrosine kinases. vandetanib 12-22 epidermal growth factor receptor Homo sapiens 92-124 22701615-2 2012 METHODS: Vandetanib (an orally bioavailable VEGFR-2 and EGFR tyrosine kinases inhibitor) was combined at 100 mg, 200 mg, or 300 mg daily with standard dosed cetuximab and irinotecan (3+3 dose-escalation design). vandetanib 9-19 epidermal growth factor receptor Homo sapiens 45-49 22258476-6 2012 Vandetanib treatment of NSCLC cells resulted in inhibition of EGFR and VEGFR-3 and inhibition of beta-estradiol-induced P-MAPK activation, demonstrating that vandetanib blocks beta-estradiol-induced EGFR signaling. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 62-66 22258476-6 2012 Vandetanib treatment of NSCLC cells resulted in inhibition of EGFR and VEGFR-3 and inhibition of beta-estradiol-induced P-MAPK activation, demonstrating that vandetanib blocks beta-estradiol-induced EGFR signaling. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 72-76 22258476-6 2012 Vandetanib treatment of NSCLC cells resulted in inhibition of EGFR and VEGFR-3 and inhibition of beta-estradiol-induced P-MAPK activation, demonstrating that vandetanib blocks beta-estradiol-induced EGFR signaling. vandetanib 158-168 epidermal growth factor receptor Homo sapiens 62-66 22258476-6 2012 Vandetanib treatment of NSCLC cells resulted in inhibition of EGFR and VEGFR-3 and inhibition of beta-estradiol-induced P-MAPK activation, demonstrating that vandetanib blocks beta-estradiol-induced EGFR signaling. vandetanib 158-168 epidermal growth factor receptor Homo sapiens 72-76 22184381-1 2012 PURPOSE: Vandetanib is an oral once-daily tyrosine kinase inhibitor with activity against vascular endothelial growth factor receptor 2 and epidermal growth factor receptor. vandetanib 9-19 epidermal growth factor receptor Homo sapiens 140-172 22075979-9 2012 Our data demonstrate that VEGFR2/EGFR inhibition through vandetanib slows down both LLC and B16.F10 tumor growth. vandetanib 57-67 epidermal growth factor receptor Homo sapiens 27-31 22500115-4 2012 Vandetanib is an oral TKI that targets VEGF receptors 2 and 3, RET, and at higher concentrations, the epidermal growth factor (EGF) receptor. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 102-140 21095630-0 2012 Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts. vandetanib 76-86 epidermal growth factor receptor Homo sapiens 0-32 21095630-13 2012 The presence of EGFR augmented RT-stimulated VEGF release; this effect was inhibited by vandetanib. vandetanib 88-98 epidermal growth factor receptor Homo sapiens 16-20 21095630-15 2012 GBM xenografts expressing EGFR exhibited greater sensitivity to both cediranib and vandetanib than EGFR-null tumors. vandetanib 83-93 epidermal growth factor receptor Homo sapiens 26-30 22258476-12 2012 CONCLUSIONS: Fulvestrant may enhance effects of vandetanib in NSCLC by blocking estrogen-driven activation of the EGFR pathway. vandetanib 48-58 epidermal growth factor receptor Homo sapiens 114-118 22429581-1 2012 BACKGROUND AND OBJECTIVE: Vandetanib is a small molecule inhibitor against vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR). vandetanib 26-36 epidermal growth factor receptor Homo sapiens 131-163 22429581-1 2012 BACKGROUND AND OBJECTIVE: Vandetanib is a small molecule inhibitor against vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR). vandetanib 26-36 epidermal growth factor receptor Homo sapiens 121-125 22336242-1 2012 BACKGROUND AND OBJECTIVE: Vandetanib is a once-daily oral multi-target inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor, and rearranged during transfection (RET) tyrosine kinases. vandetanib 26-36 epidermal growth factor receptor Homo sapiens 129-161 22025146-2 2012 Vandetanib, a once-daily oral inhibitor of RET kinase, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling, has previously shown antitumor activity in a phase II study of patients with advanced hereditary MTC. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 104-136 22158569-1 2012 Vandetanib is a small-molecule inhibitor of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and RET tyrosine kinases that has demonstrated clinical benefits in patients with medullary thyroid cancer (MTC). vandetanib 0-10 epidermal growth factor receptor Homo sapiens 97-129 22158569-1 2012 Vandetanib is a small-molecule inhibitor of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and RET tyrosine kinases that has demonstrated clinical benefits in patients with medullary thyroid cancer (MTC). vandetanib 0-10 epidermal growth factor receptor Homo sapiens 90-94 22206795-1 2012 BACKGROUND: Vandetanib is an orally available inhibitor of vascular endothelial growth factor receptor 2 and epidermal growth factor receptor and is rearranged during transfection tyrosine kinase activity. vandetanib 12-22 epidermal growth factor receptor Homo sapiens 109-141 22346266-1 2011 Vandetanib (ZD6474, Zactima ) is a novel, orally available inhibitor of different intracellular signaling pathways involved in tumor growth, progression, and angiogenesis, including vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and rearranged during transfection tyrosine kinase activity. vandetanib 12-18 epidermal growth factor receptor Homo sapiens 229-261 22346266-1 2011 Vandetanib (ZD6474, Zactima ) is a novel, orally available inhibitor of different intracellular signaling pathways involved in tumor growth, progression, and angiogenesis, including vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and rearranged during transfection tyrosine kinase activity. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 229-261 21723791-6 2011 EGFR-targeted agents such as the multitargeted TKI vandetanib and the next-generation EGFR TKIs afatinib (BIBW 2992) and PF00299804 are also under clinical investigation for the treatment of NSCLC, both alone and in combination with chemotherapy. vandetanib 51-61 epidermal growth factor receptor Homo sapiens 0-4 21970874-6 2011 Vandetanib significantly downregulated epidermal growth factor receptor (EGFR)/Erk/Akt phosphorylation as well as E2F-1 mRNA and TS mRNA/protein levels. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 39-71 21970874-6 2011 Vandetanib significantly downregulated epidermal growth factor receptor (EGFR)/Erk/Akt phosphorylation as well as E2F-1 mRNA and TS mRNA/protein levels. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 73-77 21819274-3 2011 Vandetanib is an orally available inhibitor of VEGFR and EGFR signalling and is an attractive therapeutic agent owing to the simultaneous inhibition of both pathways. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 48-52 23148184-3 2011 On the basis of a recent positive phase III clinical trial, the RET, vascular endothelial growth factor receptor (VEGFR), and epidermal growth factor receptor (EGFR) inhibitor vandetanib has received FDA approval as of April 2011 for use in the treatment of advanced medullary thyroid cancer. vandetanib 176-186 epidermal growth factor receptor Homo sapiens 126-158 21970874-8 2011 Finally, most MPM samples displayed detectable levels of EGFR and TS, the variability of which could be used for patients" stratification in future trials with vandetanib-pemetrexed-carboplatin combination. vandetanib 160-170 epidermal growth factor receptor Homo sapiens 57-61 21770481-1 2011 Vandetanib is an orally active antagonist of vascular endothelial growth factor (VEGF) receptor-2 (VEGFR-2), epidermal growth factor receptor (EGFR or HER1 or ErbB1) and RET kinase, and is now available in the US for the treatment of metastatic medullary thyroid cancer (MTC). vandetanib 0-10 epidermal growth factor receptor Homo sapiens 109-141 21770481-1 2011 Vandetanib is an orally active antagonist of vascular endothelial growth factor (VEGF) receptor-2 (VEGFR-2), epidermal growth factor receptor (EGFR or HER1 or ErbB1) and RET kinase, and is now available in the US for the treatment of metastatic medullary thyroid cancer (MTC). vandetanib 0-10 epidermal growth factor receptor Homo sapiens 100-104 21770481-1 2011 Vandetanib is an orally active antagonist of vascular endothelial growth factor (VEGF) receptor-2 (VEGFR-2), epidermal growth factor receptor (EGFR or HER1 or ErbB1) and RET kinase, and is now available in the US for the treatment of metastatic medullary thyroid cancer (MTC). vandetanib 0-10 epidermal growth factor receptor Homo sapiens 151-155 21770481-1 2011 Vandetanib is an orally active antagonist of vascular endothelial growth factor (VEGF) receptor-2 (VEGFR-2), epidermal growth factor receptor (EGFR or HER1 or ErbB1) and RET kinase, and is now available in the US for the treatment of metastatic medullary thyroid cancer (MTC). vandetanib 0-10 epidermal growth factor receptor Homo sapiens 159-164 21537841-0 2011 Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 26-30 21537841-5 2011 Cell culture experiments demonstrated that anti-proliferative effects of vandetanib resulted from inhibition of either EGFR or VEGFR-2 signalling in endothelial cells, but were associated with inhibition of EGFR signalling in tumour cells. vandetanib 73-83 epidermal growth factor receptor Homo sapiens 119-123 21537841-5 2011 Cell culture experiments demonstrated that anti-proliferative effects of vandetanib resulted from inhibition of either EGFR or VEGFR-2 signalling in endothelial cells, but were associated with inhibition of EGFR signalling in tumour cells. vandetanib 73-83 epidermal growth factor receptor Homo sapiens 128-132 21537841-6 2011 Vandetanib inhibited both EGFR and VEGFR-2 signalling in normal lung tissue and in tumour xenografts. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 26-30 21537841-7 2011 In a lung cancer model expressing an activating EGFR mutation, the activity of vandetanib was similar to that of a highly selective EGFR inhibitor (gefitinib), and markedly greater than that of a highly selective VEGFR inhibitor (vatalanib). vandetanib 79-89 epidermal growth factor receptor Homo sapiens 48-52 21537841-7 2011 In a lung cancer model expressing an activating EGFR mutation, the activity of vandetanib was similar to that of a highly selective EGFR inhibitor (gefitinib), and markedly greater than that of a highly selective VEGFR inhibitor (vatalanib). vandetanib 79-89 epidermal growth factor receptor Homo sapiens 132-136 21537841-8 2011 These data suggest that at the plasma exposures achieved in the clinic, vandetanib will significantly inhibit both VEGFR-2 and EGFR signalling, and that both inhibition of angiogenesis and direct inhibition of tumour cell growth can contribute to treatment response. vandetanib 72-82 epidermal growth factor receptor Homo sapiens 116-120 21600385-1 2011 BACKGROUND: Vandetanib (ZD6474) is an orally available inhibitor of 3 signaling pathways important in tumor progression: vascular endothelial growth factor receptor, epidermal growth factor receptor, and rearranged during transfection tyrosine kinase activity. vandetanib 12-22 epidermal growth factor receptor Homo sapiens 166-198 21282537-1 2011 PURPOSE: Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling. vandetanib 9-19 epidermal growth factor receptor Homo sapiens 102-134 21282542-1 2011 PURPOSE: Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling. vandetanib 9-19 epidermal growth factor receptor Homo sapiens 102-134 21247406-6 2011 Vandetanib, an antagonist of both vascular endothelial growth factor receptor (VEGFR) and the EGFR is currently being tested in phase II trial. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 80-84 21350000-1 2011 PURPOSE: We investigated whether vandetanib, an inhibitor of the tyrosine kinase activities of vascular endothelial growth factor receptor-2 (VEGFR-2), epidermal growth factor receptor (EGFR), and rearranged during transfection (RET), could augment the antitumor activity of radiation with or without cisplatin in preclinical in vitro and in vivo models of human head and neck squamous cell carcinoma (HNSCC). vandetanib 33-43 epidermal growth factor receptor Homo sapiens 143-147 21350000-8 2011 All vandetanib-containing treatments inhibited EGFR and Akt phosphorylation in vitro and in vivo. vandetanib 4-14 epidermal growth factor receptor Homo sapiens 47-51 21600385-1 2011 BACKGROUND: Vandetanib (ZD6474) is an orally available inhibitor of 3 signaling pathways important in tumor progression: vascular endothelial growth factor receptor, epidermal growth factor receptor, and rearranged during transfection tyrosine kinase activity. vandetanib 24-30 epidermal growth factor receptor Homo sapiens 166-198 20665703-2 2011 ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR, inhibits cell proliferation of solid tumors, including breast. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 44-48 20665703-4 2011 In order to improve the antineoplastic activity of paclitaxel, we presently investigated the effects of ZD6474 in combination with paclitaxel in EGFR and VEGFR expressing human breast cancer cell lines MCF-7 and MDA-MB-231. vandetanib 104-110 epidermal growth factor receptor Homo sapiens 145-149 20943719-2 2011 ZD6474 (vandetanib) is an ATP-competitive inhibitor of RET, epidermal growth factor receptor (EGFR), and vascular endothelial growth factor receptors kinases. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 60-92 21836817-1 2011 Vandetanib (ZD6474) is an orally bioavailable small molecule tyrosine kinase inhibitor of multiple growth factor receptors, including RET (Rearrange during transfection), vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR). vandetanib 0-10 epidermal growth factor receptor Homo sapiens 231-263 21836817-1 2011 Vandetanib (ZD6474) is an orally bioavailable small molecule tyrosine kinase inhibitor of multiple growth factor receptors, including RET (Rearrange during transfection), vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR). vandetanib 0-10 epidermal growth factor receptor Homo sapiens 219-223 21836817-1 2011 Vandetanib (ZD6474) is an orally bioavailable small molecule tyrosine kinase inhibitor of multiple growth factor receptors, including RET (Rearrange during transfection), vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR). vandetanib 12-18 epidermal growth factor receptor Homo sapiens 231-263 21836817-1 2011 Vandetanib (ZD6474) is an orally bioavailable small molecule tyrosine kinase inhibitor of multiple growth factor receptors, including RET (Rearrange during transfection), vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR). vandetanib 12-18 epidermal growth factor receptor Homo sapiens 219-223 22393954-0 2011 Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and meta-analysis. vandetanib 23-33 epidermal growth factor receptor Homo sapiens 43-47 22393954-1 2011 BACKGROUND: Vandetanib, an oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, has attracted wide interest in treatment of advanced non-small-cell lung cancer (NSCLC). vandetanib 12-22 epidermal growth factor receptor Homo sapiens 93-125 21921646-1 2011 OBJECTIVES: Vandetanib is an oral inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor and RET (REarranged during Transfection) signaling. vandetanib 12-22 epidermal growth factor receptor Homo sapiens 92-124 20943719-2 2011 ZD6474 (vandetanib) is an ATP-competitive inhibitor of RET, epidermal growth factor receptor (EGFR), and vascular endothelial growth factor receptors kinases. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 94-98 20943719-2 2011 ZD6474 (vandetanib) is an ATP-competitive inhibitor of RET, epidermal growth factor receptor (EGFR), and vascular endothelial growth factor receptors kinases. vandetanib 8-18 epidermal growth factor receptor Homo sapiens 60-92 20943719-2 2011 ZD6474 (vandetanib) is an ATP-competitive inhibitor of RET, epidermal growth factor receptor (EGFR), and vascular endothelial growth factor receptors kinases. vandetanib 8-18 epidermal growth factor receptor Homo sapiens 94-98 20943719-8 2011 This suggests that simultaneous inhibition of RET and EGFR by ZD6474 may overcome the risk of MTC cells to escape from RET blockade through compensatory over-activation of EGFR. vandetanib 62-68 epidermal growth factor receptor Homo sapiens 54-58 20943719-8 2011 This suggests that simultaneous inhibition of RET and EGFR by ZD6474 may overcome the risk of MTC cells to escape from RET blockade through compensatory over-activation of EGFR. vandetanib 62-68 epidermal growth factor receptor Homo sapiens 172-176 20859451-1 2010 Vandetanib (ZD6474) is an oral small molecule inhibitor of multiple intracellular receptor kinases, including the vascular endothelial growth factor receptor (VEGFR) -2 and epidermal growth factor receptor (EGFR). vandetanib 12-18 epidermal growth factor receptor Homo sapiens 173-205 20859451-1 2010 Vandetanib (ZD6474) is an oral small molecule inhibitor of multiple intracellular receptor kinases, including the vascular endothelial growth factor receptor (VEGFR) -2 and epidermal growth factor receptor (EGFR). vandetanib 12-18 epidermal growth factor receptor Homo sapiens 160-164 20967300-1 2010 Vandetanib is an oral inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), epidermal growth factor receptor (EGFR) and Ret tyrosine kinases involved in tumor growth, progression and angiogenesis. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 92-124 20967300-1 2010 Vandetanib is an oral inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), epidermal growth factor receptor (EGFR) and Ret tyrosine kinases involved in tumor growth, progression and angiogenesis. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 83-87 20137866-3 2010 We conducted a Phase I study of vandetanib, an inhibitor of vascular endothelial growth factor receptor 2 and epidermal growth factor receptor, in patients with newly diagnosed GBM combined with RT and temozolomide (TMZ). vandetanib 32-42 epidermal growth factor receptor Homo sapiens 110-142 20225331-2 2010 Vandetanib (ZD6474, Zactima) is an inhibitor of the vascular endothelial growth factor receptor, epidermal growth factor receptor, and rearranged during transfection (RET) tyrosine kinases, which have each been implicated in neuroblastoma pathogenesis. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 97-129 20570559-1 2010 BACKGROUND: Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and rearranged during transfection (RET) tyrosine kinases. vandetanib 12-22 epidermal growth factor receptor Homo sapiens 110-142 20570559-1 2010 BACKGROUND: Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and rearranged during transfection (RET) tyrosine kinases. vandetanib 12-22 epidermal growth factor receptor Homo sapiens 103-107 20859451-1 2010 Vandetanib (ZD6474) is an oral small molecule inhibitor of multiple intracellular receptor kinases, including the vascular endothelial growth factor receptor (VEGFR) -2 and epidermal growth factor receptor (EGFR). vandetanib 0-10 epidermal growth factor receptor Homo sapiens 173-205 20859451-1 2010 Vandetanib (ZD6474) is an oral small molecule inhibitor of multiple intracellular receptor kinases, including the vascular endothelial growth factor receptor (VEGFR) -2 and epidermal growth factor receptor (EGFR). vandetanib 0-10 epidermal growth factor receptor Homo sapiens 160-164 20661087-1 2010 INTRODUCTION: Vandetanib is a once-daily oral agent that selectively inhibits vascular endothelial growth factor receptor, epidermal growth factor receptor, and RET (REarranged during Transfection) signaling. vandetanib 14-24 epidermal growth factor receptor Homo sapiens 123-155 20225331-2 2010 Vandetanib (ZD6474, Zactima) is an inhibitor of the vascular endothelial growth factor receptor, epidermal growth factor receptor, and rearranged during transfection (RET) tyrosine kinases, which have each been implicated in neuroblastoma pathogenesis. vandetanib 12-18 epidermal growth factor receptor Homo sapiens 97-129 20139705-0 2010 ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 44-48 20139705-4 2010 We hypothesized that inhibition of phosphorylation of the EGFR and VEGFR by ZD6474 would inhibit breast cancer cell proliferation and induce apoptosis. vandetanib 76-82 epidermal growth factor receptor Homo sapiens 58-62 20139705-6 2010 ZD6474 inhibited cell proliferation in a dose-dependent manner, by blocking cell progression at the G(0)-G(1) stage, through downregulation of expression of cyclin D1 and cyclin E. In vitro, ZD6474 inhibited growth factor-induced phosphorylation of EGFR, VEGFR-2, MAPK and Akt. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 249-253 19687425-1 2009 BACKGROUND: Photosensitivity has been reported in patients who were treated with vandetanib (ZD6474), an inhibitor of epidermal growth factor receptor, vascular endothelial growth factor receptor, and the RET (rearranged during transfection) kinases. vandetanib 81-91 epidermal growth factor receptor Homo sapiens 118-150 20371720-0 2010 ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 108-140 20371720-2 2010 In this study, we investigate the effect of ZD6474 (ZACTIMA, vandetanib), a dual inhibitor for vascular endothelial growth factor receptor 2 and EGFR on growth and angiogenesis of gliomas expressing EGFRvIII. vandetanib 44-50 epidermal growth factor receptor Homo sapiens 145-149 20371720-2 2010 In this study, we investigate the effect of ZD6474 (ZACTIMA, vandetanib), a dual inhibitor for vascular endothelial growth factor receptor 2 and EGFR on growth and angiogenesis of gliomas expressing EGFRvIII. vandetanib 61-71 epidermal growth factor receptor Homo sapiens 145-149 20371720-8 2010 Albeit in lesser extent, ZD6474 also displays suppressions of U87MG/EGFR and GBM12 cells that overexpress wild-type EGFR. vandetanib 25-31 epidermal growth factor receptor Homo sapiens 68-72 20371720-8 2010 Albeit in lesser extent, ZD6474 also displays suppressions of U87MG/EGFR and GBM12 cells that overexpress wild-type EGFR. vandetanib 25-31 epidermal growth factor receptor Homo sapiens 116-120 20065189-3 2010 This open-label, phase II study assessed the efficacy of vandetanib, a selective oral inhibitor of RET, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling, in patients with advanced hereditary MTC. vandetanib 57-67 epidermal growth factor receptor Homo sapiens 153-185 19946413-1 2009 BACKGROUND: Vandetanib is a once-daily oral inhibitor of VEGFR, EGFR and RET signaling pathways. vandetanib 12-22 epidermal growth factor receptor Homo sapiens 58-62 20068097-0 2010 Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 33-37 19881951-1 2009 This study was designed to determine the effects of vandetanib, a small-molecule receptor tyrosine kinase inhibitor of vascular endothelial growth factor and epidermal growth factor receptor, on paclitaxel (PTX) tumor distribution and antitumor activity in xenograft models of human ovarian carcinoma. vandetanib 52-62 epidermal growth factor receptor Homo sapiens 158-190 19687425-1 2009 BACKGROUND: Photosensitivity has been reported in patients who were treated with vandetanib (ZD6474), an inhibitor of epidermal growth factor receptor, vascular endothelial growth factor receptor, and the RET (rearranged during transfection) kinases. vandetanib 93-99 epidermal growth factor receptor Homo sapiens 118-150 19088171-1 2009 BACKGROUND: Vandetanib (ZACTIMA; ZD6474) is a once-daily, oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling. vandetanib 12-22 epidermal growth factor receptor Homo sapiens 124-156 19220256-0 2009 Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. vandetanib 102-112 epidermal growth factor receptor Homo sapiens 5-37 19447868-1 2009 PURPOSE: Vandetanib [vascular endothelial growth factor (VEGF) receptor/epidermal growth factor receptor/RET inhibitor] has shown improvements in progression-free survival (PFS) in advanced non-small cell lung cancer in three randomized phase II studies: vandetanib versus gefitinib (study 3), docetaxel +/- vandetanib (study 6), and carboplatin-paclitaxel and/or vandetanib (study 7). vandetanib 9-19 epidermal growth factor receptor Homo sapiens 72-104 19512898-8 2009 CONCLUSIONS: Vandetanib (ZD6474), a protein tyrosine kinase inhibitor with dual anti-EGFR and anti-vascular endothelial growth factor receptor 2 action, may have contributed to the formation of corneal verticillata in our patient. vandetanib 13-23 epidermal growth factor receptor Homo sapiens 85-89 19512898-8 2009 CONCLUSIONS: Vandetanib (ZD6474), a protein tyrosine kinase inhibitor with dual anti-EGFR and anti-vascular endothelial growth factor receptor 2 action, may have contributed to the formation of corneal verticillata in our patient. vandetanib 25-31 epidermal growth factor receptor Homo sapiens 85-89 19491268-0 2009 Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo. vandetanib 11-21 epidermal growth factor receptor Homo sapiens 61-93 19491268-1 2009 Vandetanib is a novel multitarget tyrosine kinase inhibitor (TKI) that inhibits vascular endothelial growth factor receptor-2 (VEGFR-2), with additional inhibition of epidermal growth factor receptor (EGFR) and rearranged during transfection receptor signaling, which has shown promising results in clinical trials for advanced non-small cell lung cancer. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 167-199 19491268-1 2009 Vandetanib is a novel multitarget tyrosine kinase inhibitor (TKI) that inhibits vascular endothelial growth factor receptor-2 (VEGFR-2), with additional inhibition of epidermal growth factor receptor (EGFR) and rearranged during transfection receptor signaling, which has shown promising results in clinical trials for advanced non-small cell lung cancer. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 128-132 19491268-6 2009 Note that phospho-MET in PC-9/VanR was suppressed following EGFR inhibition by an irreversible EGFR-TKI, indicating that MET signaling of PC-9/VanR was dependent on EGFR signaling and that MET amplification was not the primary mechanism of resistance to vandetanib. vandetanib 254-264 epidermal growth factor receptor Homo sapiens 95-99 19491268-6 2009 Note that phospho-MET in PC-9/VanR was suppressed following EGFR inhibition by an irreversible EGFR-TKI, indicating that MET signaling of PC-9/VanR was dependent on EGFR signaling and that MET amplification was not the primary mechanism of resistance to vandetanib. vandetanib 254-264 epidermal growth factor receptor Homo sapiens 95-99 19491268-8 2009 In conclusion, the multitarget TKI vandetanib induced or selected for the EGFR T790M mutation as observed previously with highly selective EGFR-TKIs. vandetanib 35-45 epidermal growth factor receptor Homo sapiens 74-78 19491268-8 2009 In conclusion, the multitarget TKI vandetanib induced or selected for the EGFR T790M mutation as observed previously with highly selective EGFR-TKIs. vandetanib 35-45 epidermal growth factor receptor Homo sapiens 139-143 19491268-9 2009 However, vandetanib retained significant efficacy in vivo against xenografts harboring the T790M mutation, providing a strong scientific rationale for investigating vandetanib in clinical settings where acquired resistance through emergence of EGFR T790M mutations limits the effectiveness of highly selective EGFR-TKIs. vandetanib 9-19 epidermal growth factor receptor Homo sapiens 244-248 19491268-9 2009 However, vandetanib retained significant efficacy in vivo against xenografts harboring the T790M mutation, providing a strong scientific rationale for investigating vandetanib in clinical settings where acquired resistance through emergence of EGFR T790M mutations limits the effectiveness of highly selective EGFR-TKIs. vandetanib 9-19 epidermal growth factor receptor Homo sapiens 310-314 19318229-5 2009 ZD6474 and ZD1839 inhibited EGF-induced phosphorylation of EGFR, AKT and ERK, whereas VEGF-induced phosphorylation of VEGFR2 was completely inhibited with 0.1 microM SU11248. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 59-63 19332730-1 2009 PURPOSE: Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) signaling. vandetanib 9-19 epidermal growth factor receptor Homo sapiens 110-142 19332730-1 2009 PURPOSE: Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) signaling. vandetanib 9-19 epidermal growth factor receptor Homo sapiens 100-104 19332730-7 2009 Patients receiving vandetanib experienced adverse events that were manageable and generally consistent with inhibition of EGFR and VEGFR signaling, including diarrhea, rash, and hypertension. vandetanib 19-29 epidermal growth factor receptor Homo sapiens 122-126 19319137-0 2009 Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 38-42 19319137-0 2009 Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. vandetanib 12-18 epidermal growth factor receptor Homo sapiens 38-42 19319137-4 2009 Vandetanib (ZD6474, ZACTIMA), a VEGFR-2/EGFR inhibitor, was evaluated. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 33-37 19409038-1 2009 Vandetanib (ZACTIMA) is a once-daily oral anticancer drug that selectively inhibits vascular endothelial growth factor receptor, epidermal growth factor receptor, and rearranged during transfection signaling. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 129-161 19349511-0 2009 Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 97-129 19349511-0 2009 Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 87-91 19349511-0 2009 Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. vandetanib 12-18 epidermal growth factor receptor Homo sapiens 87-91 19349511-1 2009 Vandetanib is a novel, orally available inhibitor of different intracellular signaling pathways involved in tumor growth, progression, and angiogenesis: vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and REarranged during Transfection tyrosine kinase activity. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 200-232 19088171-1 2009 BACKGROUND: Vandetanib (ZACTIMA; ZD6474) is a once-daily, oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling. vandetanib 33-39 epidermal growth factor receptor Homo sapiens 124-156 19362942-7 2009 Dual inhibition of EGFR and VEGF pathways has also been accomplished by the novel agents vandetanib and XL647, which are able to target both pathways. vandetanib 89-99 epidermal growth factor receptor Homo sapiens 19-23 18381602-6 2008 A significant synergistic growth inhibitory effect was observed with the combination of bortezomib and each EGFR inhibitor in all cell lines (combination index, CI, range 0.10-0.55), which was accompanied by a significant induction in apoptosis by the combined treatment with bortezomib, cetuximab and vandetanib. vandetanib 302-312 epidermal growth factor receptor Homo sapiens 108-112 18936474-1 2008 PURPOSE: Vandetanib is a once-daily, oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling. vandetanib 9-19 epidermal growth factor receptor Homo sapiens 103-135 17393165-0 2008 Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. vandetanib 69-79 epidermal growth factor receptor Homo sapiens 38-42 18694994-4 2008 RESULTS: Multitargeted inhibitor vandetanib (ZD6474) inhibited the growth and the phosphorylation of Akt and its effector p70S6 kinase in both wild-type and EGFR inhibitor-resistant human colon, prostate, and breast cancer cells. vandetanib 33-43 epidermal growth factor receptor Homo sapiens 157-161 18694994-4 2008 RESULTS: Multitargeted inhibitor vandetanib (ZD6474) inhibited the growth and the phosphorylation of Akt and its effector p70S6 kinase in both wild-type and EGFR inhibitor-resistant human colon, prostate, and breast cancer cells. vandetanib 45-51 epidermal growth factor receptor Homo sapiens 157-161 18694994-9 2008 Moreover, vandetanib inhibits VEGFR-1 activation, cell proliferation, and migration, suggesting its potential utility in patients resistant to EGFR inhibitors. vandetanib 10-20 epidermal growth factor receptor Homo sapiens 31-35 18364248-2 2008 In the present study, we investigated the therapeutic efficacy of vandetanib (ZD6474), an inhibitor of VEGFR-2, EGFR and RET tyrosine kinases, in an orthotopic model of MPM. vandetanib 66-76 epidermal growth factor receptor Homo sapiens 104-108 18520295-0 2008 Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer. vandetanib 117-127 epidermal growth factor receptor Homo sapiens 70-102 18520295-0 2008 Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer. vandetanib 129-135 epidermal growth factor receptor Homo sapiens 70-102 18520295-1 2008 Vandetinib is a novel, selective dual inhibitor of the vascular endothelial growth factor receptor pathway and epidermal growth factor receptor pathway. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 111-143 18248788-7 2008 All these biological effects seem to depend on the activity of gefitinib and vandetanib blocking activity towards p-EGFR mediated pathways. vandetanib 77-87 epidermal growth factor receptor Homo sapiens 116-120 18379357-1 2008 INTRODUCTION: Vandetanib (ZACTIMA) is a once-daily, oral anticancer drug that selectively inhibits vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) signaling. vandetanib 14-24 epidermal growth factor receptor Homo sapiens 155-187 18379357-1 2008 INTRODUCTION: Vandetanib (ZACTIMA) is a once-daily, oral anticancer drug that selectively inhibits vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) signaling. vandetanib 14-24 epidermal growth factor receptor Homo sapiens 145-149 17393165-13 2008 These results suggest that the anti-VEGFR2 antitumor activity of vandetanib is enhanced by RT as presumably the activity seen in EGFR- tumors is due to antiangiogenic activity, whereas the anti-EGFR antitumor activity dominates in EGFR+ tumors such that RT enhancement is not observed. vandetanib 65-75 epidermal growth factor receptor Homo sapiens 37-41 17393165-13 2008 These results suggest that the anti-VEGFR2 antitumor activity of vandetanib is enhanced by RT as presumably the activity seen in EGFR- tumors is due to antiangiogenic activity, whereas the anti-EGFR antitumor activity dominates in EGFR+ tumors such that RT enhancement is not observed. vandetanib 65-75 epidermal growth factor receptor Homo sapiens 129-133 17393165-13 2008 These results suggest that the anti-VEGFR2 antitumor activity of vandetanib is enhanced by RT as presumably the activity seen in EGFR- tumors is due to antiangiogenic activity, whereas the anti-EGFR antitumor activity dominates in EGFR+ tumors such that RT enhancement is not observed. vandetanib 65-75 epidermal growth factor receptor Homo sapiens 129-133 21479415-1 2008 The objective of this study was to examine the antitumor effect of ZD6474, an orally available inhibitor of the vascular endothelial growth factor receptor-2 (VEGFR-2) and the epidermal growth factor receptor (EGFR), on tumor growth in an orthotopic metastatic brain tumor model. vandetanib 67-73 epidermal growth factor receptor Homo sapiens 160-164 21479415-6 2008 Western blot analysis revealed that the autophosphorylation of EGFR and Akt was increasingly decreased with ZD6474 treatment in lung and brain endothelial cells and the MDA-MB-435 cell line. vandetanib 108-114 epidermal growth factor receptor Homo sapiens 63-67 21479415-7 2008 MTT assay also showed that the in vitro antitumor activity of ZD6474 was dependent on EGFR tyrosine kinase inhibition at a higher dose. vandetanib 62-68 epidermal growth factor receptor Homo sapiens 86-90 18177496-3 2008 Gefitinib is an inhibitor of epidermal growth factor receptor tyrosine kinase activity (EGFR) and vandetanib selectively targets vascular endothelial growth factor receptor-2 (VEGFR-2) with additional activity against VEGFR-3, EGFR and RET kinase receptors. vandetanib 98-108 epidermal growth factor receptor Homo sapiens 177-181 17393165-0 2008 Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. vandetanib 69-79 epidermal growth factor receptor Homo sapiens 38-42 17393165-1 2008 PURPOSE: Vandetanib (ZD6474, Zactima) is a novel, orally available inhibitor of vascular endothelial growth factor receptor-2 (VEGFR2) tyrosine kinase activity with additional activity against epidermal growth factor receptor (EGFR) tyrosine kinase. vandetanib 9-19 epidermal growth factor receptor Homo sapiens 193-225 17393165-1 2008 PURPOSE: Vandetanib (ZD6474, Zactima) is a novel, orally available inhibitor of vascular endothelial growth factor receptor-2 (VEGFR2) tyrosine kinase activity with additional activity against epidermal growth factor receptor (EGFR) tyrosine kinase. vandetanib 9-19 epidermal growth factor receptor Homo sapiens 128-132 17393165-1 2008 PURPOSE: Vandetanib (ZD6474, Zactima) is a novel, orally available inhibitor of vascular endothelial growth factor receptor-2 (VEGFR2) tyrosine kinase activity with additional activity against epidermal growth factor receptor (EGFR) tyrosine kinase. vandetanib 21-27 epidermal growth factor receptor Homo sapiens 193-225 17393165-1 2008 PURPOSE: Vandetanib (ZD6474, Zactima) is a novel, orally available inhibitor of vascular endothelial growth factor receptor-2 (VEGFR2) tyrosine kinase activity with additional activity against epidermal growth factor receptor (EGFR) tyrosine kinase. vandetanib 21-27 epidermal growth factor receptor Homo sapiens 128-132 17393165-3 2008 This study aimed to evaluate the schedule-dependent interaction of clinically relevant dosing of vandetanib with RT in human head and neck cancer models that had been characterized as EGFR positive (EGFR+) or negative (EGFR-) in order to begin differentiating vandetanib and RT interactions at the level of antitumor (EGFR) or antivascular (VEGFR2) activities. vandetanib 97-107 epidermal growth factor receptor Homo sapiens 184-188 17393165-8 2008 RESULTS: Vandetanib alone caused regression in EGFR+ but not EGFR- tumors and RT therapy alone was similar in both tumor types. vandetanib 9-19 epidermal growth factor receptor Homo sapiens 47-51 17393165-11 2008 CONCLUSIONS: The combination of vandetanib and RT is active in both EGFR+ and EGFR- HNSCC tumor xenografts, however, vandetanib alone is only active in EGFR+ xenografts. vandetanib 32-42 epidermal growth factor receptor Homo sapiens 68-72 17393165-11 2008 CONCLUSIONS: The combination of vandetanib and RT is active in both EGFR+ and EGFR- HNSCC tumor xenografts, however, vandetanib alone is only active in EGFR+ xenografts. vandetanib 32-42 epidermal growth factor receptor Homo sapiens 78-82 17393165-11 2008 CONCLUSIONS: The combination of vandetanib and RT is active in both EGFR+ and EGFR- HNSCC tumor xenografts, however, vandetanib alone is only active in EGFR+ xenografts. vandetanib 32-42 epidermal growth factor receptor Homo sapiens 78-82 17393165-12 2008 EGFR+ tumor response to vandetanib and RT was independent of treatment sequencing, but concomitant treatment was superior to sequencing in EGFR- tumors. vandetanib 24-34 epidermal growth factor receptor Homo sapiens 0-4 17975157-0 2007 Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model. vandetanib 41-51 epidermal growth factor receptor Homo sapiens 126-158 17889445-0 2007 Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. vandetanib 45-51 epidermal growth factor receptor Homo sapiens 26-30 17889445-7 2007 In vivo, the combined blockade of VEGFR2 and EGFR by ZD6474 blocked pleural effusion formation and angiogenesis and enhanced the antivascular and antitumor effects of radiation therapy in the orthotopic human lung cancer model and was superior to chemoradiotherapy. vandetanib 53-59 epidermal growth factor receptor Homo sapiens 35-39 17414626-1 2007 ZD6474 is a novel, orally available inhibitor of vascular endothelial growth factor receptor kinase insert domain receptor/flk-1 tyrosine kinase activity with additional activity against the epidermal growth factor receptor-1 tyrosine kinase. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 191-223 17631646-0 2007 Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase. vandetanib 88-94 epidermal growth factor receptor Homo sapiens 113-117 17631646-1 2007 ZD6474 is a vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 68-100 17631646-1 2007 ZD6474 is a vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 58-62 17631646-3 2007 Results indicated that ZD6474 treatment inhibited EGFR phosphorylation and led to a dose- and time-dependent decrease in NPC cell (CNE-1, CNE-2 and C666-1) proliferation. vandetanib 23-29 epidermal growth factor receptor Homo sapiens 50-54 17912240-2 2007 ZD6474 is an orally active, selective inhibitor of the vascular endothelial growth factor receptor, epidermal growth factor receptor, and rearranged during transfection tyrosine kinases. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 100-132 17414626-10 2007 Immunohistochemistry of tumor samples following treatment with ZD6474 resulted in a reduction of the activated and phosphorylated epidermal growth factor receptor, whereas total epidermal growth factor receptor levels were comparable with control tumors. vandetanib 63-69 epidermal growth factor receptor Homo sapiens 130-162 17414626-11 2007 On the basis of Western blot analysis, ZD6474 provides inhibition of tumor angiogenesis through an anti-vascular endothelial growth factor receptor-2 mechanism and inhibition of cancer cell growth through an anti-epidermal growth factor receptor mechanism. vandetanib 39-45 epidermal growth factor receptor Homo sapiens 213-245 16332356-6 2006 Under the same experimental conditions, ZD6474 inhibited the expression of phosphorylated EGFR in all cell lines while the effect on p-Erk1/2 was dependent on cellular invasive characteristics. vandetanib 40-46 epidermal growth factor receptor Homo sapiens 90-94 17145834-0 2006 Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. vandetanib 34-40 epidermal growth factor receptor Homo sapiens 106-138 17145834-2 2006 This study investigated the interactions between ZD6474, an inhibitor of tyrosine kinase activities of vascular endothelial growth factor receptor-2 and epidermal growth factor receptor (EGFR), gemcitabine, and ionizing radiation in human pancreatic cancer cells and analyzed the molecular mechanisms underlying this combination. vandetanib 49-55 epidermal growth factor receptor Homo sapiens 153-185 17145834-6 2006 Moreover, ZD6474 inhibited phosphorylation of EGFR and Akt and triggered cell apoptosis. vandetanib 10-16 epidermal growth factor receptor Homo sapiens 46-50 17409986-1 2006 INTRODUCTION: ZD6474 (vandetanib) is an orally available inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor, and RET receptor tyrosine kinase activity. vandetanib 14-20 epidermal growth factor receptor Homo sapiens 115-147 17409986-1 2006 INTRODUCTION: ZD6474 (vandetanib) is an orally available inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor, and RET receptor tyrosine kinase activity. vandetanib 22-32 epidermal growth factor receptor Homo sapiens 115-147 17136225-3 2006 Vandetanib is a novel multitargeted kinase inhibitor exhibiting potent activity against vascular endothelial growth factor receptor-2 (VEGFR-2; kinase insert domain-containing receptor [KDR]) and, to a lesser extent, epidermal growth factor receptor (EGFR) and RET kinase. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 217-249 17136225-3 2006 Vandetanib is a novel multitargeted kinase inhibitor exhibiting potent activity against vascular endothelial growth factor receptor-2 (VEGFR-2; kinase insert domain-containing receptor [KDR]) and, to a lesser extent, epidermal growth factor receptor (EGFR) and RET kinase. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 136-140 17136225-5 2006 In addition to its antiangiogenic effects, vandetanib acts against EGFR, which is overexpressed or mutated in several solid tumors. vandetanib 43-53 epidermal growth factor receptor Homo sapiens 67-71 16937523-5 2006 Treatment with gefitinib or ZD6474 also inhibited the expression of EGFR downstream signal molecules, p-Erk1/2 and p-Akt, although the magnitude of these effects varied between treatments and cell lines. vandetanib 28-34 epidermal growth factor receptor Homo sapiens 68-72 16688779-0 2006 Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. vandetanib 99-105 epidermal growth factor receptor Homo sapiens 124-128 16688779-3 2006 ZD6474 is an orally available, small molecule inhibitor of VEGF receptor-2 (VEGFR-2), EGFR and RET tyrosine kinase activity. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 77-81 16688779-5 2006 EXPERIMENTAL DESIGN: The anti-tumor activity in vitro and in vivo of ZD6474 and/or cetuximab was tested in human cancer cell lines with a functional EGFR autocrine pathway. vandetanib 69-75 epidermal growth factor receptor Homo sapiens 149-153 16721126-2 2006 RECENT FINDINGS: There are studies exploring the anti-tumor efficacy of dual inhibitors, such as the compound ZD6474, which combines in the same molecule an anti-tyrosine kinase activity against the epidermal growth factor receptor and the vascular endothelial growth factor receptor. vandetanib 110-116 epidermal growth factor receptor Homo sapiens 199-231 16891475-0 2006 Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases. vandetanib 127-133 epidermal growth factor receptor Homo sapiens 162-166 16891475-4 2006 We evaluated the in vitro antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR) and RET tyrosine kinase activity, and oxaliplatin using three combination schedules: ZD6474 before oxaliplatin, oxaliplatin before ZD6474, and concurrent exposure. vandetanib 48-54 epidermal growth factor receptor Homo sapiens 118-122 17272980-5 2007 ZD6474 is a dual epidermal growth factor receptor and vascular endothelial growth factor receptor 2 small-molecule tyrosine kinase inhibitor; sorafenib is an oral kinase inhibitor of Raf-1 and is also active against vascular endothelial growth factor receptors 2 and 3, platelet-derived growth factor receptor beta, and c-KIT. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 17-49 17243944-2 2007 Vandetanib targets key signaling pathways in cancer by inhibiting VEGFR-dependent tumor angiogenesis, and EGFR- and RET-dependent tumor cell proliferation and survival. vandetanib 0-10 epidermal growth factor receptor Homo sapiens 67-71 17308046-6 2007 The effects of ZD6474 (ZACTIMA), a small-molecule inhibitor of VEGFR2 and EGFR tyrosine kinases, were then studied in vitro using human lung cancer and microvascular endothelial cells. vandetanib 15-21 epidermal growth factor receptor Homo sapiens 64-68 17308046-7 2007 In vitro, ZD6474 inhibited EGFR, VEGFR2, mitogen-activated protein kinase and Akt phosphorylation, EGF- and VEGF-induced proliferation, and endothelial cell tube formation and also induced apoptosis. vandetanib 10-16 epidermal growth factor receptor Homo sapiens 27-31 17308046-9 2007 The inhibition of both VEGFR2 and EGFR signaling pathways by ZD6474 resulted in profound antiangiogenic, antivascular, and antitumor effects. vandetanib 61-67 epidermal growth factor receptor Homo sapiens 24-28 17203163-3 2007 ZD6474 is a potent VEGF receptor-2 (VEGFR-2) tyrosine kinase inhibitor which also has activity against the epidermal growth factor receptor (EGFR) tyrosine kinase. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 107-139 17203163-3 2007 ZD6474 is a potent VEGF receptor-2 (VEGFR-2) tyrosine kinase inhibitor which also has activity against the epidermal growth factor receptor (EGFR) tyrosine kinase. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 37-41 17203163-6 2007 In vitro ZD6474 displayed antiproliferative effects on HNSCC cells and inhibition of VEGFR-2 and EGFR pathways. vandetanib 9-15 epidermal growth factor receptor Homo sapiens 86-90 17203163-8 2007 These results suggest that ZD6474 has the potential to inhibit two key pathways in tumor growth via inhibition of VEGF-dependent tumor angiogenesis and via inhibition of EGFR-dependent tumor cell proliferation. vandetanib 27-33 epidermal growth factor receptor Homo sapiens 170-174 15928657-0 2005 ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 30-34 16377413-0 2006 ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 25-29 16377413-4 2006 This article focuses on ZD6474, an inhibitor of EGFR and VEGF receptor signaling in combination with RT. vandetanib 24-30 epidermal growth factor receptor Homo sapiens 48-52 16377413-7 2006 We also discuss ZD6474 in the context of anti-EGFR therapy resistance. vandetanib 16-22 epidermal growth factor receptor Homo sapiens 46-50 16783964-1 2006 ZD6474 is a novel, orally active inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase, with some additional activity against epidermal growth factor receptor (EGFR) tyrosine kinase. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 157-189 16783964-1 2006 ZD6474 is a novel, orally active inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase, with some additional activity against epidermal growth factor receptor (EGFR) tyrosine kinase. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 94-98 15905307-1 2005 BACKGROUND: ZD6474 selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor and epidermal growth factor receptor. vandetanib 12-18 epidermal growth factor receptor Homo sapiens 120-152 16061883-4 2005 We have investigated the antitumor and antiangiogenic effect of ZD6474, an inhibitor of both VEGFR and EGFR signaling as a single agent and in combination with ionizing radiation. vandetanib 64-70 epidermal growth factor receptor Homo sapiens 94-98 15928657-5 2005 In addition to its antiangiogenic properties, ZD6474 also has activity against the epidermal growth factor receptor (EGFR) tyrosine kinase, which could impart a direct inhibitory effect on tumour cell growth and survival. vandetanib 46-52 epidermal growth factor receptor Homo sapiens 83-115 15928657-5 2005 In addition to its antiangiogenic properties, ZD6474 also has activity against the epidermal growth factor receptor (EGFR) tyrosine kinase, which could impart a direct inhibitory effect on tumour cell growth and survival. vandetanib 46-52 epidermal growth factor receptor Homo sapiens 117-121 12684431-0 2003 Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. vandetanib 21-27 epidermal growth factor receptor Homo sapiens 150-182 15709198-4 2005 ZD6474 is an orally available, small molecule, dual VEGF receptor-2 (VEGFR-2) and EGFR tyrosine kinase inhibitor. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 70-74 15367698-2 2004 The purpose of this study was to examine the effects of ZD6474, an inhibitor of inhibitor of VEGF receptor (VEGFR) tyrosine kinase with additional activity against EGF receptor (EGFR), on tumor growth and angiogenesis in an orthotopic model of gastric cancer. vandetanib 56-62 epidermal growth factor receptor Homo sapiens 94-106 15367698-2 2004 The purpose of this study was to examine the effects of ZD6474, an inhibitor of inhibitor of VEGF receptor (VEGFR) tyrosine kinase with additional activity against EGF receptor (EGFR), on tumor growth and angiogenesis in an orthotopic model of gastric cancer. vandetanib 56-62 epidermal growth factor receptor Homo sapiens 109-113 15367698-4 2004 EGF-mediated activation of EGFR and Erk-1/2 was decreased in tumor cells after ZD6474 treatment. vandetanib 79-85 epidermal growth factor receptor Homo sapiens 27-31 14760102-5 2004 ZD6474 is a small molecule VEGF flk-1/KDR (VEGFR-2) tyrosine kinase inhibitor that also demonstrates inhibitory activity against EGFR tyrosine kinase. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 44-48 15867237-0 2005 A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. vandetanib 32-38 epidermal growth factor receptor Homo sapiens 92-124 15867237-1 2005 PURPOSE: To determine the efficacy and safety of ZD6474, an orally available inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase with additional activity against the epidermal growth factor receptor (EGFR) tyrosine kinase, in patients with previously treated metastatic breast cancer. vandetanib 49-55 epidermal growth factor receptor Homo sapiens 199-231 15867237-1 2005 PURPOSE: To determine the efficacy and safety of ZD6474, an orally available inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase with additional activity against the epidermal growth factor receptor (EGFR) tyrosine kinase, in patients with previously treated metastatic breast cancer. vandetanib 49-55 epidermal growth factor receptor Homo sapiens 138-142 15604279-0 2004 Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. vandetanib 80-86 epidermal growth factor receptor Homo sapiens 31-63 15604279-1 2004 ZD6474 is an inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2/KDR) tyrosine kinase, with additional activity against epidermal growth factor receptor (EGFR) tyrosine kinase. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 136-168 15604279-1 2004 ZD6474 is an inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2/KDR) tyrosine kinase, with additional activity against epidermal growth factor receptor (EGFR) tyrosine kinase. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 74-78 15604279-7 2004 To clarify the involvement of the deletional mutation of EGFR in the cellular sensitivity to ZD6474, we examined the effect of this agent on HEK293 stable transfectants expressing deletional EGFR that designed as the same deletion site observed in PC-9 cells (293-pDelta15). vandetanib 93-99 epidermal growth factor receptor Homo sapiens 57-61 15604279-9 2004 ZD6474 inhibited the phosphorylation of the mutant EGFR by 10-fold compared with cells with wild-type EGFR. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 51-55 15604279-10 2004 In conclusion, the findings suggested that a small in-frame deletion in the EGFR increased the cellular sensitivity to ZD6474. vandetanib 119-125 epidermal growth factor receptor Homo sapiens 76-80 15623642-2 2004 ZD6474 (N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine) is a potent VEGF receptor 2 (KDR) tyrosine kinase inhibitor (TKI) that has additional activity versus the epidermal growth factor receptor. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 206-238 15623642-2 2004 ZD6474 (N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine) is a potent VEGF receptor 2 (KDR) tyrosine kinase inhibitor (TKI) that has additional activity versus the epidermal growth factor receptor. vandetanib 8-98 epidermal growth factor receptor Homo sapiens 206-238 15596048-1 2004 ZD6474 is a novel, orally available inhibitor of vascular endothelial growth factor (VEGF) receptor-2 (KDR) tyrosine kinase, with additional activity against epidermal growth factor receptor (EGFR) tyrosine kinase. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 158-190 15596048-1 2004 ZD6474 is a novel, orally available inhibitor of vascular endothelial growth factor (VEGF) receptor-2 (KDR) tyrosine kinase, with additional activity against epidermal growth factor receptor (EGFR) tyrosine kinase. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 192-196 15596048-6 2004 In addition, ZD6474 showed dose-dependent inhibition of EGFR phosphorylation in PC-9 cells, but inhibition was only partial in PC-9/ZD cells. vandetanib 13-19 epidermal growth factor receptor Homo sapiens 56-60 15596048-7 2004 ZD6474-mediated inhibition of tyrosine residue phosphorylation (Tyr992 and Tyr1045) on EGFR was greater in PC-9 cells than in PC-9/ZD cells. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 87-91 15596048-8 2004 These findings suggest that the inhibition of EGFR phosphorylation by ZD6474 can contribute a significant, direct growth-inhibitory effect in tumor cell lines dependent on EGFR signaling for growth and/or survival. vandetanib 70-76 epidermal growth factor receptor Homo sapiens 46-50 15596048-8 2004 These findings suggest that the inhibition of EGFR phosphorylation by ZD6474 can contribute a significant, direct growth-inhibitory effect in tumor cell lines dependent on EGFR signaling for growth and/or survival. vandetanib 70-76 epidermal growth factor receptor Homo sapiens 172-176 15596048-13 2004 These studies demonstrate that the additional EGFR TKI activity may contribute significantly to the antitumor efficacy of ZD6474, in particular in those tumors that are dependent on continued EGFR-signaling for proliferation or survival. vandetanib 122-128 epidermal growth factor receptor Homo sapiens 46-50 15596048-13 2004 These studies demonstrate that the additional EGFR TKI activity may contribute significantly to the antitumor efficacy of ZD6474, in particular in those tumors that are dependent on continued EGFR-signaling for proliferation or survival. vandetanib 122-128 epidermal growth factor receptor Homo sapiens 192-196 15596048-14 2004 In addition, these results provide a preclinical rationale for further investigation of ZD6474 as a potential treatment option for both EGFR-TKI-sensitive and EGFR-TKI-resistant tumors. vandetanib 88-94 epidermal growth factor receptor Homo sapiens 136-140 15596048-14 2004 In addition, these results provide a preclinical rationale for further investigation of ZD6474 as a potential treatment option for both EGFR-TKI-sensitive and EGFR-TKI-resistant tumors. vandetanib 88-94 epidermal growth factor receptor Homo sapiens 159-163 12684431-5 2003 EXPERIMENTAL DESIGN: We tested the effects of ZD6474 on EGFR phosphorylation in cell expressing functional epidermal growth factor receptor (EGFR) and the antiproliferative and the proapoptotic activity of ZD6474 alone or in combination taxanes in human cancer cell lines with functional EGFR but lacking VEGFR-2. vandetanib 46-52 epidermal growth factor receptor Homo sapiens 56-60 12684431-5 2003 EXPERIMENTAL DESIGN: We tested the effects of ZD6474 on EGFR phosphorylation in cell expressing functional epidermal growth factor receptor (EGFR) and the antiproliferative and the proapoptotic activity of ZD6474 alone or in combination taxanes in human cancer cell lines with functional EGFR but lacking VEGFR-2. vandetanib 46-52 epidermal growth factor receptor Homo sapiens 107-139 12684431-5 2003 EXPERIMENTAL DESIGN: We tested the effects of ZD6474 on EGFR phosphorylation in cell expressing functional epidermal growth factor receptor (EGFR) and the antiproliferative and the proapoptotic activity of ZD6474 alone or in combination taxanes in human cancer cell lines with functional EGFR but lacking VEGFR-2. vandetanib 46-52 epidermal growth factor receptor Homo sapiens 141-145 12684431-5 2003 EXPERIMENTAL DESIGN: We tested the effects of ZD6474 on EGFR phosphorylation in cell expressing functional epidermal growth factor receptor (EGFR) and the antiproliferative and the proapoptotic activity of ZD6474 alone or in combination taxanes in human cancer cell lines with functional EGFR but lacking VEGFR-2. vandetanib 46-52 epidermal growth factor receptor Homo sapiens 141-145 12684431-7 2003 RESULTS: ZD6474 causes a dose-dependent inhibition of EGFR phosphorylation in mouse NIH-EGFR fibroblasts and human MCF-10A ras breast cancer cells, two cell lines that overexpress the human EGFR. vandetanib 9-15 epidermal growth factor receptor Homo sapiens 88-92 12684431-8 2003 ZD6474 treatment resulted in a dose-dependent inhibition of soft agar growth in seven human cell lines (breast, colon, gastric, and ovarian) with functional EGFR but lacking VEGFR-2. vandetanib 0-6 epidermal growth factor receptor Homo sapiens 157-161